Literature DB >> 1920428

Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution.

J N Varghese1, P M Colman.   

Abstract

An atomic model of the tetrameric surface glycoprotein neuraminidase of influenza virus A/Tokyo/3/67 has been built and refined based on X-ray diffraction data at 2.2 A resolution. The crystallographic residual is 0.21 for data between 6 and 2.2 A resolution and the r.m.s. deviations from ideal geometry are 0.02 A for bond lengths and 3.9 degrees for bond angles. The model includes amino acid residues 83 to 469, four oligosaccharide structures N-linked at asparagine residues 86, 146, 200 and 234, a single putative Ca2+ ion site, and 85 water molecules. One of the oligosaccharides participates in a novel crystal contact. The folding pattern is a beta-sheet propeller as described earlier and details of the intramolecular interactions between the six beta-sheets are presented. Strain-invariant residues are clustered around the propeller axis on the upper surface of the molecule where they line the wall of a cavity into which sialic has been observed to bind. Strain-variable residues implicated in binding to antibodies surround this site.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1920428     DOI: 10.1016/0022-2836(91)80068-6

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  66 in total

1.  Mutation signature in neuraminidase gene of avian influenza H9N2/G1 in Egypt.

Authors:  Zienab Mosaad; Abdelsatar Arafa; Hussein A Hussein; Mohamed A Shalaby
Journal:  Virusdisease       Date:  2017-05-23

2.  Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases.

Authors:  J N Varghese; P M Colman; A van Donkelaar; T J Blick; A Sahasrabudhe; J L McKimm-Breschkin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  Crystallization of biologically active hemagglutinin-neuraminidase glycoprotein dimers proteolytically cleaved from human parainfluenza virus type 1.

Authors:  T Takimoto; W G Laver; K G Murti; A Portner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

Review 4.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05

5.  A structural and energetics analysis of the binding of a series of N-acetylneuraminic-acid-based inhibitors to influenza virus sialidase.

Authors:  N R Taylor; M von Itzstein
Journal:  J Comput Aided Mol Des       Date:  1996-06       Impact factor: 3.686

6.  Modification of Cys-837 identifies an actin-binding site in the beta-propeller protein scruin.

Authors:  S Sun; M Footer; P Matsudaira
Journal:  Mol Biol Cell       Date:  1997-03       Impact factor: 4.138

7.  A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.

Authors:  M T Murrell; M Porotto; O Greengard; N Poltoratskaia; A Moscona
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase.

Authors:  J N Varghese; V C Epa; P M Colman
Journal:  Protein Sci       Date:  1995-06       Impact factor: 6.725

9.  Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

Authors:  N T Wetherall; T Trivedi; J Zeller; C Hodges-Savola; J L McKimm-Breschkin; M Zambon; F G Hayden
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

10.  Role of secondary sialic acid binding sites in influenza N1 neuraminidase.

Authors:  Jeffrey C Sung; Adam W Van Wynsberghe; Rommie E Amaro; Wilfred W Li; J Andrew McCammon
Journal:  J Am Chem Soc       Date:  2010-03-10       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.